<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01761435</url>
  </required_header>
  <id_info>
    <org_study_id>TraNsgripe1-2</org_study_id>
    <nct_id>NCT01761435</nct_id>
  </id_info>
  <brief_title>Clinical Trial Evaluating Efficacy and Safety of One Dose Versus Two Doses of Influenza Vaccination</brief_title>
  <acronym>TraNsgripe</acronym>
  <official_title>Randomized, Comparative and Prospective Clinical Trial Evaluating Efficacy and Safety of a Dose of Seasonal Flu Vaccine Compared to Two Doses of Vaccine for Prevention of Influenza in Solid Organ Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Network for Research in Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, multicenter, open label trial to compare safety and efficacy of two doses
      stationary flu vaccination vs one doses in Solid Organ Transplant Recipients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purposes of this study are:

        1. Evaluate the efficacy and safety of a double dose of seasonal flu vaccine compared to a
           single dose.

        2. Determine the specific cellular immune response produced after the first and second
           vaccine doses of seasonal flu vaccine by in vitro stimulation of specific memory cells
           (A and B flu viruses).

        3. Evaluate the humoral immune response produced after one dose vs two doses of seasonal
           flu vaccine by the measure of serum antibody levels.

        4. Evaluate clinical efficacy of stationary flu vaccine in solid organ transplant
           recipients.

        5. Evaluate a long term cellular and humoral response(1 year) of seasonal flu vaccine.

        6. Characterize the genetic expression profile of immune response after the flu vaccine in
           solid organ transplant recipients by means of a genetic sub-study.

        7. Characterize the flu vaccine effect (one dose and two doses) through the antibody
           anti-HLA(human leukocyte antigen), and its influence on the rejection rate in solid
           organ transplant recipients, by means of immunologic sub-study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rates</measure>
    <time_frame>At 5, 10, 15 weeks, and 12 months after the first vaccine dose</time_frame>
    <description>Difference in seroconversion rates in both treatment groups at 5, 10, 15 weeks, and 12 months after the first vaccine dose (percent of patients with 4 x increase in the pre-vaccination titers).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postvaccination antibody titers</measure>
    <time_frame>At 5, 10, 15 weeks, and 12 months after the first vaccine dose.</time_frame>
    <description>Geometric average postvaccination antibody titers and rate of increase between pre-and post-vaccination geometric mean, post-vaccination seroprotection rate (or percentage of individuals with a titer 1 / 40 as measured by RIH).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety.</measure>
    <time_frame>At 5, 10, 15 weeks, and 12 months after the first vaccine dose</time_frame>
    <description>Occurrence of grade 3 or 4 toxicity, death, hospitalization, retransplantation, acute rejection and chronic rejection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>At 5, 10, 15 weeks, and 12 months after the first vaccine dose</time_frame>
    <description>Detection of clinical cases of influenza following immunization. Nasal swabs to confirm infection with influenza virus by RT-PCR (Reverse transcription polymerase chain reaction).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody anti-HLA</measure>
    <time_frame>At 5, 10, 15 weeks, and 12 months after the first vaccine dose</time_frame>
    <description>Characterize the flu vaccine effect (one dose and two doses) through the antibody anti-HLA levels, ant its influence on the rejection rate in solid organ transplant recipients, by means of immunologic sub-study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cellular response</measure>
    <time_frame>At 5, 10, 15 weeks, and 12 months after the first vaccine dose</time_frame>
    <description>Determination of the T cells specific immune response measured by production of INFg, IL-2 and IL-4 in the cytoplasm of CD4+ and CD8 + (mononuclear cells) specific for influenza virus by direct immunofluorescence and flow cytometry analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical complications</measure>
    <time_frame>At 5, 10, 15 weeks, and 12 months after the first vaccine dose</time_frame>
    <description>Clinical severity (hospitalization, ICU admission, death, rejection). Time to clinical stability will be register.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">499</enrollment>
  <condition>Infection in Solid Organ Transplant Recipients</condition>
  <arm_group>
    <arm_group_label>Influenza vaccine, second administration after 5 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first one.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Influenza vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine</intervention_name>
    <description>Patients will be randomized at 1:1 rate and open label fashion, according to centers, and time elapsed since transplant and type of organ transplanted to one of this two interventions :
A arm (usual treatment): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.
B arm (experimental branch): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first dose.
The follow-up of both arms will be at 5, 10 and 15 weeks and one year after the baseline.</description>
    <arm_group_label>Influenza vaccine, second administration after 5 weeks</arm_group_label>
    <arm_group_label>Influenza vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Solid organ transplant recipient.

          2. 16 years or older.

          3. More than 30 days after transplantation.

          4. Negative pregnancy test for women of childbearing potential

          5. The patient must give informed consent

        Exclusion Criteria:

          1. No written informed consent.

          2. Acute rejection within 15 days prior to vaccination.

          3. Pregnancy.

          4. Hypersensitivity to the active substance, any of the excipients and waste, for
             example: eggs, egg albumin, chicken proteins.

          5. History of a previous serious reaction to immunization (eg Guillain-Barré syndrome).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julian De la Torre Cisneros, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>COMPLEJO HOSPITALARIO REGIONAL REINA SOFÍA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco López Medrano, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario 12 de Octubre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia Muñoz García, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL GENERAL GREGORIO MARAÑÓN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesús Fortun Abete, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramon y Cajal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joán Gavaldà Santapau, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITALS VALL D'HEBRON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jordi Carratalá Fernández, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Asunción Moreno Camacho, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL CLINIC I PROVINCIAL DE BARCELONA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Miguel Montejo Baranda, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARIO DE CRUCES</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marino Blanes Julia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Fe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alejandro Suarez Benjumea, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>COMPLEJO HOSPITALARIO REGIONAL VIRGEN MACARENA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Fariñas Álvarez, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Marqués de Valdecilla</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Elisa Cordero Matia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Masqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Bilbao</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Cruces</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital la Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.reipi.org/</url>
    <description>The Spanish Network for the Research in Infectious Diseases (REIPI) is based in research groups of high standards and professional level. REIPI´s aim is to generate scientific knowledge in the field of the infectious diseases, in areas ranging from basic</description>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2013</study_first_posted>
  <last_update_submitted>April 30, 2015</last_update_submitted>
  <last_update_submitted_qc>April 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Solid Organ Transplant Recipients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

